Advanced

Splanchnic vein thrombosis in myeloproliferative neoplasms : Risk factors for recurrences in a cohort of 181 patients

De Stefano, V.; Vannucchi, A. M.; Ruggeri, M.; Cervantes, F.; Alvarez-Larrán, A.; Iurlo, A.; Randi, M. L.; Pieri, L.; Rossi, E. and Guglielmelli, P., et al. (2016) In Blood Cancer Journal 6(11).
Abstract

We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR:... (More)

We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Cancer Journal
volume
6
issue
11
publisher
Nature Publishing Group
external identifiers
  • scopus:84994624429
  • wos:000391806500006
ISSN
2044-5385
DOI
10.1038/bcj.2016.103
language
English
LU publication?
yes
id
7efe5bbf-0ff7-4f5a-894b-0299ccb2dff7
date added to LUP
2016-12-07 11:33:48
date last changed
2017-11-16 15:07:38
@article{7efe5bbf-0ff7-4f5a-894b-0299ccb2dff7,
  abstract     = {<p>We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.</p>},
  articleno    = {e493},
  author       = {De Stefano, V. and Vannucchi, A. M. and Ruggeri, M. and Cervantes, F. and Alvarez-Larrán, A. and Iurlo, A. and Randi, M. L. and Pieri, L. and Rossi, E. and Guglielmelli, P. and Betti, S. and Elli, E. and Finazzi, M. C. and Finazzi, G. and Zetterberg, E. and Vianelli, N. and Gaidano, G. and Nichele, I. and Cattaneo, D. and Palova, M. and Ellis, M. H. and Cacciola, E. and Tieghi, A. and Hernandez-Boluda, J. C. and Pungolino, E. and Specchia, G. and Rapezzi, D. and Forcina, A. and Musolino, C. and Carobbio, A. and Griesshammer, M. and Barbui, T.},
  issn         = {2044-5385},
  language     = {eng},
  month        = {11},
  number       = {11},
  publisher    = {Nature Publishing Group},
  series       = {Blood Cancer Journal},
  title        = {Splanchnic vein thrombosis in myeloproliferative neoplasms : Risk factors for recurrences in a cohort of 181 patients},
  url          = {http://dx.doi.org/10.1038/bcj.2016.103},
  volume       = {6},
  year         = {2016},
}